表紙
市場調査レポート

ティッシュエンジニアリング・細胞療法・移植:世界の製品、技術、市場の機会(2009〜2018年)

Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities Worldwide 2009-2018

発行 MedMarket Diligence, LLC 商品コード 108198
出版日 ページ情報 英文 314 Pages; 74 Exhibits; 147 Profiles
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
ティッシュエンジニアリング・細胞療法・移植:世界の製品、技術、市場の機会(2009〜2018年) Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities Worldwide 2009-2018
出版日: 2010年02月16日 ページ情報: 英文 314 Pages; 74 Exhibits; 147 Profiles

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、ティッシュエンジニアリング、細胞療法、組織移植/細胞移植市場の現状と技術開発動向、現在の市場規模と今後の予測などについて、分野別にまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 ティッシュエンジニアリングと細胞療法業界の背景

  • 概要
  • 定義
  • 主な処置
  • 開発上の課題
  • 臨床のアンメットニーズ
  • ティッシュエンジニアリングおよび細胞療法に基づくビジネスモデル
  • スケジュール
  • 同分野の課題
  • 競争激化

第2章 臨床疾患と治療のニーズ

  • イントロダクション
  • 歯科
  • 耳鼻咽喉科/呼吸器系/心肺
  • 胃腸科
  • 婦人科
  • 神経科
  • 眼科
  • 臓器移植
  • 整形外科
  • 皮膚/外皮
  • 泌尿器科

第3章 製品および企業が支援する技術開発(承認済みと開発中)

  • イントロダクション
  • 心血管・血管
  • 歯科
  • 耳鼻咽喉科/呼吸器系/心肺
  • 胃腸科
  • 婦人科
  • 神経科
  • 眼科
  • 臓器移植および関連治療
  • 整形外科
  • 皮膚/外皮
  • 泌尿器科

第4章 市場、潜在的市場、競合企業のシェア

  • 世界の組織エンジニアド製品市場

第5章 企業プロファイル(147社)

付録

目次
Product Code: S520

This report examines the status of technologies, applications and markets for tissue engineering, cell therapy and tissue/cell transplantation. The report reviews therapeutic tissue engineering, tissue reconstruction, cell therapies, tissue/organ transplantation and related technologies under various stages of development at nearly150 companies. The report details the technology development, projected market introduction dates and/or current and forecast market size and competitor shares for products being developed to address major causes of death and disease spanning applications in cardiovascular, neurological, orthopaedic, urological, skin, dental, ophthalmological, gastrointestinal, organ transplant, cancer and others. The report details the status of product development and assesses the current and forecast worldwide market for tissue engineering, cell therapy and transplantation.

The report provides market size and share data, with forecast market data to 2018, for the U.S., Europe, Asia/Pacific and Rest of World.

The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast and assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

Table of Contents

Executive Summary

Section 1: TISSUE ENGINEERING AND CELL THERAPY INDUSTRY BACKGROUND

  • 1.1 Overview
  • 1.2 Definitions
  • 1.3 Growth of Key Procedures
  • 1.4 Development Challenges
    • 1.4.1 Material-based Tissue Replacements
    • 1.4.2 Allograft-derived Tissue Replacements
    • 1.4.3 Cell and Tissue Engineered Products
  • 1.5 Unmet Clinical Needs
  • 1.6 Business Models Based On Tissue Engineering and Cell Therapy
  • 1.7 Timescales
  • 1.8 Sector Challenges
    • 1.8.1 Reimbursement
    • 1.8.2 Regulatory
      • 1.8.2.1 United States
      • 1.8.2.2 China
      • 1.8.2.3 European Union
    • 1.8.3 Cost-effectiveness
    • 1.8.4 Clinical Issues
    • 1.8.5 Economic Downturns Worldwide
  • 1.9 Competition Intensity
    • 1.9.1 Industry Focus
    • 1.9.2 Investment Levels
    • 1.9.3 Investor Returns

Section 2: Clinical Disorders and Therapy Needs

  • 2.1 Introduction
    • 2.1.1 Stem Cell Banking
    • 2.1.2 Cardiovascular and Vascular
    • 2.1.3 Coronary Heart Disease
    • 2.1.4 Myocardial Infarction
    • 2.1.5 Congestive Heart Failure
    • 2.1.6 Dysfunctional Heart Valves
    • 2.1.7 Peripheral Vascular Disorders
    • 2.1.8 Abdominal Aortic Aneurysm
  • 2.2 Cancer
    • 2.2.1 Urology
      • 2.2.1.1 Bladder
      • 2.2.1.2 Kidney/Renal Cell
      • 2.2.1.3 Prostate
    • 2.2.2 Neurology
    • 2.2.3 Ob/Gyn
      • 2.2.3.1 Breast
      • 2.2.3.2 Ovarian
      • 2.2.3.3 Endometrial
      • 2.2.3.4 Cervix Uteri
    • 2.2.4 Orthopedic/Bone
    • 2.2.5 Gastrointestinal/Gastroenterology
      • 2.2.5.1 Colorectal
      • 2.2.5.2 Gastric
      • 2.2.5.3 Pancreas
      • 2.2.5.4 Liver
      • 2.2.5.5 Esophageal
    • 2.2.6 Head and Neck
      • 2.2.6.1 Oral
      • 2.2.6.2 Throat
      • 2.2.6.3 Thyroid
    • 2.2.7 Hematopoietic
      • 2.2.7.1 Leukemia
      • 2.2.7.2 Lymphoma
    • 2.2.8 Respiratory
      • 2.2.8.1 Lung
    • 2.2.9 Dermatology (Skin Cancer)
  • 2.3 Dental
    • 2.3.1 Missing Teeth
    • 2.3.2 Periodontal Disease
  • 2.4 ENT/Respiratory/Cardiopulmonary
  • 2.5 Trachea
    • 2.5.1 Respiratory Epithelial Cells
  • 2.6 Gastrointestinal
    • 2.6.1 Esophagus
    • 2.6.2 Colon/Small Intestine
  • 2.7 Gynecology
  • 2.8 Neurological
    • 2.8.1 Stroke
    • 2.8.2 Parkinson' s Disease
    • 2.8.3 Alzheimer' s Disease
    • 2.8.4 Epilepsy
    • 2.8.5 Traumatic Brain Injury
    • 2.8.6 Central Nervous System and Spinal Cord Disease
      • 2.8.6.1 Amyotrophic Lateral Sclerosis
      • 2.8.6.2 Multiple Sclerosis
      • 2.8.6.3 Neuromuscular/Muscular Dystrophy
  • 2.9 Ophthalmology
    • 2.9.1 Cornea
    • 2.9.2 Retina
  • 2.10 Organ Transplantation
    • 2.10.1 Liver
    • 2.10.2 Heart
    • 2.10.3 Kidney
    • 2.10.4 Pancreas
  • 2.11 Orthopedic
    • 2.11.1 Non-Union Fractures
    • 2.11.2 Cartilage Damage and Repair
    • 2.11.3 Ligament Damage
    • 2.11.4 Vertebral Disc Damage
    • 2.11.5 Bone Graft Materials
  • 2.12 Skin/Integumentary
    • 2.12.1 Burns
    • 2.12.2 Diabetic Ulcers
    • 2.12.3 Venous Ulcers
    • 2.12.4 Plastic and Reconstructive Surgery
  • 2.13 Urological
    • 2.13.1 Incontinence
    • 2.13.2 Kidney Disease
    • 2.13.3 Bladder

Section 3: Product & Company-Sponsored Technology Developments (Approved and in Development)

  • 3.1 Introduction
  • 3.2 Cancer
    • 3.2.1 Types of Cancer Gene Therapies
    • 3.2.2 Direct Delivery of Gene Proteins to Tumor
    • 3.2.3 Medications to Boost the Immune System/Antibodies
    • 3.2.4 Anti-Angiogenesis
    • 3.2.5 Vaccines
    • 3.2.6 Expanded Numbers of Cord Blood Stem Cells
  • 3.3 Cardiovascular and Vascular
  • 3.4 Dental
  • 3.5 ENT/Respiratory/Cardiopulmonary
  • 3.6 Gastrointestinal
  • 3.7 Gynecology
  • 3.8 Neurological
  • 3.9 Ophthalmology
  • 3.10 Organ Transplantation and Related Therapies
    • 3.10.1 Liver
    • 3.10.2 Kidney
    • 3.10.3 Pancreas/Diabetes Therapies
    • 3.10.4 Cryopreservation of Cells and Tissues
  • 3.11 Orthopedic
  • 3.12 Skin/Integumentary
    • 3.12.1 Plastic and Reconstructive Surgery
  • 3.13 Urological

Section 4: Markets, Potential Markets, and COMPETITOR SHARES

  • 4.1 Worldwide Potential Market for Tissue Engineered Products
  • 4.2 Cardiovascular and Vascular
  • 4.3 Neurological
  • 4.4 Orthopedic
  • 4.5 Urological
  • 4.6 Skin/Integumentary
  • 4.7 Dental
  • 4.8 Organ Transplantation and Preservation
  • 4.9 Ophthalmology
  • 4.10 General, Gastrointestinal, Gynecologic and Other
  • 4.11 Cancer
  • 4.12 Cord Blood and Cell Banking

Section 5: Company profiles

  • 5.1 3DM Inc.
  • 5.2 Aastrom Bioscience Inc.
  • 5.3 Acorda Therapeutics Inc.
  • 5.4 Advanced BioHealing, Inc.
  • 5.5 Advanced Cell Technology, Inc.
  • 5.6 Advanced Medical Solutions PLC
  • 5.7 Aeolus Pharmaceuticals
  • 5.8 Aldagen, Inc.
  • 5.9 Alexion Pharmaceuticals
  • 5.10 Angioblast Systems, Inc.
  • 5.11 Angiotech Pharmaceuticals, Inc.
  • 5.12 Ariad Pharmaceuticals Inc.
  • 5.13 Arteriocyte Medical Systems, Inc.
  • 5.14 Athersys, Inc.
  • 5.15 Avax Technologies Inc.
  • 5.16 Avita Medical Limited
  • 5.17 Baxter International Inc.
  • 5.18 BeFutur Biotechnologies
  • 5.19 Bio Nova International
  • 5.20 Biocomposites
  • 5.21 Biocoral Inc.
  • 5.22 Bioheart Inc.
  • 5.23 BioHybrid Technologies
  • 5.24 BioLife Solutions Inc.
  • 5.25 Biomet, Inc.
  • 5.26 BioMimetic Therapeutics
  • 5.27 BioSante Pharmaceuticals, Inc.
  • 5.28 BioSyntech
  • 5.29 BioTissue Technologies GmbH
  • 5.30 Boston Scientific Corporation
  • 5.31 BrainStorm Cell Therapeutics, Inc.
  • 5.32 Breonics Perfusion Technologies, Inc.
  • 5.33 BTG International Ltd.
  • 5.34 California Stem Cells Inc.
  • 5.35 Capstone Therapeutics
  • 5.36 Celgene Corporation
  • 5.37 CellECT Bio Inc.
  • 5.38 Cellerix SA
  • 5.39 CellSeed, Inc.
  • 5.40 CellTran Ltd.
  • 5.41 Cellular Dynamics International
  • 5.42 Centocor Ortho Biotech, Inc.
  • 5.43 Cerco Medical
  • 5.44 co.don AG
  • 5.45 ConMed Linvatec
  • 5.46 Cook Group
  • 5.47 CorCell Companies, Inc.
  • 5.48 Cryo-Cell International, Inc.
  • 5.49 CryoLife, Inc.
  • 5.50 Curis Inc.
  • 5.51 Cyclacel Pharmaceuticals, Inc.
  • 5.52 Cytograft Tissue Engineering
  • 5.53 Cytomatrix LLC
  • 5.54 Cytori Therapeutics Inc.
  • 5.55 ES Cell International
  • 5.56 Exactech, Inc.
  • 5.57 Excorp Medical, Inc.
  • 5.58 FibroGen, Inc.
  • 5.59 Fidia Advanced Biopolymers/Anika Therapeutics, Inc.
  • 5.60 Forticell Bioscience, Inc.
  • 5.61 Gamida Cell Ltd.
  • 5.62 Garnet BioTherapeutics
  • 5.63 Genta, Inc.
  • 5.64 GenVec, Inc.
  • 5.65 Genzyme Corporation
  • 5.66 Geron Corporation
  • 5.67 Glycotex, Inc.
  • 5.68 HepaLife Technologies, Inc.
  • 5.69 Hospira
  • 5.70 Humacyte, Inc.
  • 5.71 InCytu Inc.
  • 5.72 Inion Ltd.
  • 5.73 Innogenetics
  • 5.74 InnovaCell Biotechnologie GmbH
  • 5.75 Integra LifeSciences Inc.
  • 5.76 ISTO Technologies Inc.
  • 5.77 Johnson & Johnson Inc.
    • 5.77.1 Ethicon Biosurgery
    • 5.77.2 DePuy
  • 5.78 Kensey Nash
  • 5.79 Kerecis EHF
  • 5.80 LifeCell Inc.
  • 5.81 LifeStem Inc. (Calba Tech, Inc.)
  • 5.82 Living Cell Technologies Ltd.
  • 5.83 Lonza Group Ltd.
  • 5.84 MaxCyte
  • 5.85 Medtronic
  • 5.86 Mesoblast Limited
  • 5.87 MG Biotherapeutics, LLC
  • 5.88 MicroIslet Inc.
  • 5.89 Miltenyi Biotec
  • 5.90 Musculoskeletal Transplant Foundation
  • 5.91 Natural Implant
  • 5.92 NellOne Therapeutics, Inc.
  • 5.93 NeoStem, Inc.
  • 5.94 Neuralstem, Inc.
  • 5.95 NeuroGeneration, Inc.
  • 5.96 NeuroNova AB
  • 5.97 Neurotech
  • 5.98 Novartis International AG
  • 5.99 Novo Nordisk A/B
  • 5.100 Novocell Inc.
  • 5.101 OncoMed Pharmaceuticals
  • 5.102 Organogenesis Inc.
  • 5.103 Organovo, Inc.
  • 5.104 Orthovita
  • 5.105 OSI Pharmaceuticals
  • 5.106 Osiris Therapeutics Inc.
  • 5.107 Osteotech, Inc.
  • 5.108 Pioneer Surgical Technologies
  • 5.109 Pluristem Therapeutics Inc.
  • 5.110 Poly-Med, Inc.
  • 5.111 Polyganics BV
  • 5.112 ProChon Biotech, Ltd.
  • 5.113 Progenitor Cell Therapy Inc.
  • 5.114 ProNeuron Biotechnologies, Inc.
  • 5.115 Protein Polymer Technologies Inc.
  • 5.116 ReGen Biologics Inc.
  • 5.117 Reinnervate Ltd.
  • 5.118 ReNeuron Ltd.
  • 5.119 Revivicor, Inc.
  • 5.120 RTI Biologics, Inc.
  • 5.121 Sanofi-Aventis
  • 5.122 Sciperio Inc.
  • 5.123 Serica Technologies, Inc./Allergan
  • 5.124 Sernova Corp.
  • 5.125 Smith & Nephew Ltd.
  • 5.126 SpineSmith Partners, LP
  • 5.127 Stem Cell Pharma Inc.
  • 5.128 Stem Cell Sciences UK Ltd.
  • 5.129 Stem Cell Therapy International, Inc./Histostem Co. Ltd.
  • 5.130 StemCell Technologies Inc.
  • 5.131 StemCells Inc.
  • 5.132 Stryker Corporation
  • 5.133 Synovis Life Technologies, Inc.
  • 5.134 Targeted Genetics Corporation
  • 5.135 TEI Biosciences Inc.
  • 5.136 Tengion, Inc .
  • 5.137 Tepha Inc.
  • 5.138 Theracell, Inc.
  • 5.139 ThermoGenesis Corp.
  • 5.140 TiGenix N.V.
  • 5.141 Transition Therapeutics Inc.
  • 5.142 TriStem Corporation
  • 5.143 Vesta Therapeutics
  • 5.144 ViaCell/PerkinElmer
  • 5.145 Vital Therapies, Inc.
  • 5.146 Vitrolife AB
  • 5.147 Zimmer, Inc.

Appendix: Company Directory

List of Exhibit

  • Exhibit ES-1: Worldwide Tissue Engineering & Cell Therapy Market, 2009-2018
  • Exhibit ES-2: Worldwide Tissue Engineering & Cell Therapy Market, by Geographic Segment, 2009-2018
  • Exhibit ES-3: Worldwide Tissue Engineering & Cell Therapy Market, By Segment, 2009-2018
  • Exhibi ES-4: Worldwide Tissue Engineering & Cell Therapy Market by Manufacturer, 2009
  • Exhibit 2-1: Leading Companies in Stem Cell Banking
  • Exhibit 2-2: Potential For Cardiovascular Tissue Engineering - Incidences of Applicable Surgical Procedures, 2010
  • Exhibit 2-3: Prevalence of Cardiovascular Disease in Adults Age 20 and Older by Age and Sex, Percent of the Population, 2003 - 2006
  • Exhibit 2-4: Incidence of Cardiovascular Disease by Age and Sex, Per 1,000 Person Years, 1980 - 2003
  • Exhibit 2-5: Incidence of Myocardial Infarction by Age and Sex, 1987 - 2004
  • Exhibit 2-6: Prevalence of Heart Failure in the United States by Age and Sex, Percent of Population
  • Exhibit 2-7: Incidence of New Cancer Cases Worldwide by Region, 2007
  • Exhibit 2-8: Female Breast Cancer Incidence and Mortality Rates by Race and Ethnicity in the U.S., 2002 - 2006, Rate per 100,000
  • Exhibit 2-9: Colorectal Cancer Incidence and Mortality Rates by Race/Ethnicity and Sex in the U.S., 2001 - 2005, Rate per 100,000
  • Exhibit 3-1: Companies with Cancer Therapies Marketed or in Development
  • Exhibit 3-2: Key Competitors in Tissue Engineering and Cell Therapies for Cardiovascular Applications
  • Exhibit 3-3: Key Competitors in Tissue Engineering and Cell Therapies for Dental and Oral Surgery Applications
  • Exhibit 3-4: Key Competitors in Tissue Engineering and Cell Therapies for ENT, Respiratory and Cardiopulmonary Applications
  • Exhibit 3-5: Key Competitors in Tissue Engineering and Cell Therapies for Gastrointestinal Applications
  • Exhibit 3-6: Key Competitors in Tissue Engineering and Cell Therapies for Gynecology Applications
  • Exhibit 3-7: Key Competitors in Tissue Engineering and Cell Therapies for Neurology Applications
  • Exhibit 3-8: Key Competitors in Tissue Engineering and Cell Therapies for Ophthalmology Applications
  • Exhibit 3-9: Key Competitors in Tissue Engineering and Cell Therapies for Organ Transplant, Organ Preservation and Related Therapies
  • Exhibit 3-10: Key Competitors in Tissue Engineering and Cell Therapies for Orthopedic, Musculoskeletal, and Spine Applications
  • Exhibit 3-11: Key Competitors in Tissue Engineering and Cell Therapies for Skin/Integumentary Applications
  • Exhibit 3-11: Key Competitors in Tissue Engineering and Cell Therapies for Urological Applications
  • Exhibit 4-1: Worldwide Tissue Engineering & Cell Therapy Market, 2009-2018
  • Exhibit 4-2: Worldwide Tissue Engineering & Cell Therapy Market, by Geographic Segment, 2009-2018
  • Exhibit 4-3: Worldwide Tissue Engineering & Cell Therapy Market, By Segment, 2009-2018
  • Exhibit 4-4: Worldwide Tissue Engineering & Cell Therapy Market, Cardiology, 2009-2018
  • Exhibit 4-5: Worldwide Tissue Engineering & Cell Therapy Market, Cardiology, by Geographic Segment, 2009-2018
  • Exhibit 4-6: Worldwide Tissue Engineering & Cell Therapy Market, Cardiology, by Manufacturer, 2009
  • Exhibit 4-7: Worldwide Tissue Engineering & Cell Therapy Market, Neurology, 2009-2018
  • Exhibit 4-8: Worldwide Tissue Engineering & Cell Therapy Market, Neurology, by Geographic Segment, 2009-2018
  • Exhibit 4-9: Worldwide Tissue Engineering & Cell Therapy Market, Neurology, by Manufacturer, 2009
  • Exhibit 4-10: Worldwide Tissue Engineering & Cell Therapy Market, Orthopedic/Spine, 2009-2018
  • Exhibit 4-11: Worldwide Tissue Engineering & Cell Therapy Market, Orthopedic/Spine, by Geographic Segment, 2009-2018
  • Exhibit 4-12: Worldwide Tissue Engineering & Cell Therapy Market, Orthopedic/Spine, by Manufacturer, 2009
  • Exhibit 4-13: Worldwide Tissue Engineering & Cell Therapy Market, Urology, 2009-2018
  • Exhibit 4-14: Worldwide Tissue Engineering & Cell Therapy Market, Urology, by Geographic Segment, 2009-2018
  • Exhibit 4-15: Worldwide Tissue Engineering & Cell Therapy Market, Urology, by Manufacturer, 2009
  • Exhibit 4-16: Worldwide Tissue Engineering & Cell Therapy Market, Skin/Integumentary, 2009-2018
  • Exhibit 4-17: Worldwide Tissue Engineering & Cell Therapy Market, Skin/Integumentary, by Geographic Segment, 2009-2018
  • Exhibit 4-18: Worldwide Tissue Engineering & Cell Therapy Market, Skin/Integumentary, by Manufacturer, 2009
  • Exhibit 4-19: Worldwide Tissue Engineering & Cell Therapy Market, Dental/Oral, 2009-2018
  • Exhibit 4-20: Worldwide Tissue Engineering & Cell Therapy Market, Dental/Oral, by Geographic Segment, 2009-2018
  • Exhibit 4-21: Worldwide Tissue Engineering & Cell Therapy Market, Dental/Oral, by Manufacturer, 2009
  • Exhibit 4-22: Worldwide Tissue Engineering & Cell Therapy Market, Organ Transplant/Preservation, 2009-2018
  • Exhibit 4-23: Worldwide Tissue Engineering & Cell Therapy Market, Organ Transplant/Preservation, by Geographic Segment, 2009-2018
  • Exhibit 4-24: Worldwide Tissue Engineering & Cell Therapy Market, Organ Transplant/Preservation, by Manufacturer, 2009
  • Exhibit 4-25: Worldwide Tissue Engineering & Cell Therapy Market, Ophthalmology, 2009-2018
  • Exhibit 4-26: Worldwide Tissue Engineering & Cell Therapy Market, Ophthalmology, by Geographic Segment, 2009-2018
  • Exhibit 4-27: Worldwide Tissue Engineering & Cell Therapy Market, Ophthalmology, by Manufacturer, 2009
  • Exhibit 4-28: Worldwide Tissue Engineering & Cell Therapy Market, General, Gastroenterology, Gynecology, Others, 2009-2018
  • Exhibit 4-29: Worldwide Tissue Engineering & Cell Therapy Market, General, Gastroenterology, Gynecology, Others, by Geographic Segment, 2009-2018
  • Exhibit 4-30: Worldwide Tissue Engineering & Cell Therapy Market, General, GI, Gyn, Others, by Manufacturer, 2009
  • Exhibit 4-31: Worldwide Tissue Engineering & Cell Therapy Market, Cancer, 2009-2018
  • Exhibit 4-32: Worldwide Tissue Engineering & Cell Therapy Market, Cancer, by Geographic Segment, 2009-2018
  • Exhibit 4-33: Worldwide Tissue Engineering & Cell Therapy Market, Cancer, by Manufacturer, 2009
  • Exhibit 4-34: Worldwide Tissue Engineering & Cell Therapy Market, Cord Blood and Cell Banking, 2009-2018
  • Exhibit 4-35: Worldwide Tissue Engineering & Cell Therapy Market, Cord Blood and Cell Banking, by Geographic Segment, 2009-2018
  • Exhibit 4-36: Worldwide Tissue Engineering & Cell Therapy Market, Cord Blood and Cell Banking, by Manufacturer, 2009
  • Exhibit 5-1: Advanced Cell Technology, Inc. and Subsidiary Consolidated Statements of Operations for the Years Ended December 31, 2008 and 2007
  • Exhibit 5-2: Clinical Trials Being Conducted by Mesoblast and Angioblast
  • Exhibit 5-3: Angioblast' s Lead Products in Development
  • Exhibit 5-4: Baxter Sales by Business, 2008, $ Billions
  • Exhibit 5-5: BTG International' s Revenue-Producing Products and Sales Data
  • Exhibit 5-6: Celgene' s Leading Product Candidates
  • Exhibit 5-7: CryoLife Revenue by Product, 2008
  • Exhibit 5-8: Genzyme Approved/Marketed Cell Therapy - Derived Products
  • Exhibit 5-9: Geron' s hESC-derived Product Candidates
  • Exhibit 5-10: Osteotech Revenues, Year End 2006 - 2008 (000)
  • Exhibit 5-11: Proneuron' s Developmental Product Pipeline
  • Exhibit 5-12: RTI Biologics' Revenues, Years Ended Dec. 31, 2006 - 2008, (000)
  • Exhibit 5-13: RTI Biologics' Products by Distributor
  • Exhibit 5-14: TEI Biosciences' Products, Applications and Marketing Partners
Back to Top